Blood sample: Blood samples for analysis of circulating tumour HPVDNA
Study summary
The goal of this clinical trial is to determine the value of circulating tumour HPV DNA (human papilloma virus DNA found in the blood) at diagnosis, during treatment, and in the follow-up of patients diagnosed and treated for throat cancer caused by HPV.
The main question to answer is if the presence of HPV DNA in the blood one month after the treatment is useful in detecting remaining tumour or relapse within two years after treatment.
The participants will be asked to provide blood tests:
1. before treatment
2. weekly during the treatment
3. on all scheduled follow-up appointments
4. on all unplanned appointments where a relapse is suspected
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Only patients with an HPV-positive primary tumour will eventually be eligible for inclusion.
Non-detectable ctHPVDNA at diagnosis will not be a reason for exclusion.
2. Age \>18 years.
3. Able to give informed consent.
4. The patient will be treated with curative intent.
Exclusion Criteria:
Patients with a short life expectancy, psychiatric or addictive disorders, or other medical conditions which might impair patient compliance may be excluded at the discretion of the investigator.
Primary outcome measure(s)
The sensitivity of detectable ctHPVDNA one month after (c)RT completion — From inclusion to two years after treatment To determine if detectable ctHPVDNA one month post (C)RT is useful to detect residual or recurrent tumours diagnosed within two years.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
